Survival by sidedness of metastatic colorectal cancer (mCRC) treated with epidermal growth factor receptor antibodies (EGFR-Ab) in the refractory setting: A population-based study of 1509 patients

Eva Segelov, Craig Earle, Alan Venook, R Saskin, Layla Mofid, Simron Singh

Research output: Contribution to conferenceAbstractOther

Original languageEnglish
Number of pages1
DOIs
Publication statusPublished - 2018

Cite this

@conference{cee2332de6954762ab818b03e62e43c7,
title = "Survival by sidedness of metastatic colorectal cancer (mCRC) treated with epidermal growth factor receptor antibodies (EGFR-Ab) in the refractory setting: A population-based study of 1509 patients",
author = "Eva Segelov and Craig Earle and Alan Venook and R Saskin and Layla Mofid and Simron Singh",
year = "2018",
doi = "10.1093/annonc/mdx393.112",
language = "English",

}

Survival by sidedness of metastatic colorectal cancer (mCRC) treated with epidermal growth factor receptor antibodies (EGFR-Ab) in the refractory setting: A population-based study of 1509 patients. / Segelov, Eva; Earle, Craig; Venook, Alan; Saskin, R; Mofid, Layla; Singh, Simron.

2018.

Research output: Contribution to conferenceAbstractOther

TY - CONF

T1 - Survival by sidedness of metastatic colorectal cancer (mCRC) treated with epidermal growth factor receptor antibodies (EGFR-Ab) in the refractory setting: A population-based study of 1509 patients

AU - Segelov, Eva

AU - Earle, Craig

AU - Venook, Alan

AU - Saskin, R

AU - Mofid, Layla

AU - Singh, Simron

PY - 2018

Y1 - 2018

U2 - 10.1093/annonc/mdx393.112

DO - 10.1093/annonc/mdx393.112

M3 - Abstract

ER -